| 1. |
- McKelvey, Maureen, 1965, et al.
(författare)
-
Effects of position in research network on innovative performance: Evidence the Pharmaceutical Industry
- 2012
-
Ingår i: International Schumpeter Conference, Brisbane, Australia, July 2012.
-
Konferensbidrag (refereegranskat)abstract
- This paper explores how and why collaboration with different types of partners and the position within a research network can affect firms’ innovative performance in terms of product innovations. A detailed empirical analysis is carried out in the biotechnology and pharmaceutical industry. This industry is characterized by a rapidly developing, complex, and dispersed knowledge base, where one would expect positive benefits from collaboration and the position within a network for innovative output. The paper uses a unique dataset in pharmaceutical cancer research based on scientific co-publications and new drug approvals. We apply social network analysis and count data regressions. We observe that collaboration with a diverse set of partners from academia and the network position in terms of eigenvector centrality is positively related to product innovation. However, we do not find a general positive association between collaboration, particularly with biotechnology companies, and product innovation or between central network positions and product innovation. Therefore, these results require a re-assessment of the role of scientific collaboration and biotechnology companies in the development of the pharmaceutical industry.
|
|
| 2. |
- McKelvey, Maureen, 1965, et al.
(författare)
-
Research network position and innovative performance: Evidence from the pharmaceutical industry
- 2013
-
Ingår i: Workshop on the role of hospitals in innovation, Center for Technology, innovation and culture, University of Oslo.
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- Building upon the literature demonstrating the importance of collaborative research and networks for the development of new pharmaceuticals, this paper describes co-publication networks in phar- maceutical cancer research and analyzes how the position within these networks and collaboration with different partners is related to the product innovation of both pharmaceutical and biotechnol- ogy firms. This paper analyzes these issues through econometric analysis as well as social network analysis using a unique dataset based on scientific co-publications, new drug approvals, and firm level data. We observe that the number of organizations in co-publication networks expands faster than the collaborations within the networks. Global pharmaceutical companies tend to be highly connected and occupy central positions in the co-publication networks. Direct and indirect linkages, particularly to academic institutions, are beneficial for product innovations. In contrast to most of the existing literature, we find that co-publication of pharmaceutical companies with biotechnol- ogy companies is a rather rare event – and we do not find a significant association to the firm’s innovative performance.
|
|
| 3. |
- McKelvey, Maureen, 1965, et al.
(författare)
-
The influence of collaboration on firm publications: Evidence from pharmaceutical cancer research
- 2014
-
Ingår i: Conference Innovation and Entrepreneurship in Health Care & Life Sciences. 2nd annual InnovHealth network..
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- This paper addresses whether, and how, collaboration in research affects the firm's later propensity to get a new drug approved. Cancer is in focus. This paper was presented at the Conference Innovation and Entrepreneurship in Health Care & Life Sciences. 2nd annual InnovHealth network. IIE organized this conference, 11-12 Dec 2014, Gothenburg, Sweden.
|
|
| 4. |
|
|
| 5. |
- McKelvey, Tomas, 1966, et al.
(författare)
-
Product Innovation Success Based on Cancer Research in the Pharmaceutical Industry: Co-publication networks and the effects of partners
- 2016
-
Ingår i: Industry and Innovation. - : Informa UK Limited. - 1366-2716 .- 1469-8390. ; 23:5, s. 383-406
-
Tidskriftsartikel (refereegranskat)abstract
- This paper builds upon the literature which provides conflicting theoretical insights and empirical results concerning the importance of companies’ collaborative relations, their position within a network of collaborative relations and the effects on their innovative performance. Taking the importance of collaborations and networks in the pharmaceutical industry into account, the paper untangles the influence of the firm’s co-publication relations with different types of partners and its network position on the company’s product innovation in a specific disease area—cancer. We find rather robust evidence that in particular, companies’ indirect connections within the co-publication network, including connections to academic institutions and biotechnology companies, support product innovation. In contrast to evidence in the strategic alliance literature, direct co-publication links to biotechnology companies do not support product innovation in terms of new cancer medications.
|
|
| 6. |
- McKelvey, Tomas, 1966, et al.
(författare)
-
The influence of collaboration on firm publications: Evidence from pharmaceutical cancer research
- 2015
-
Ingår i: Academy of Management proceedings, Vancouver, Canada. Canada, 7-11 August 2015.. ; 2015:14244, s. 1-30
-
Konferensbidrag (refereegranskat)abstract
- Although bio-pharmaceutical companies engage intensely in collaboration as well as in scientific publications it is not well understood how and why the choice of distinct partner types affects the quality of companies’ scientific publications. We contribute to this gap in the existing literature by analyzing whether collaboration with particular types of partners and whether network embeddedness influences the quality of publications in cancer research, and specifically of the scientific publications of biotech and of pharmaceutical companies. Our empirical analysis employs two different measures for scientific quality, publication in top-tier journals and the number of forward citations. The results suggest that publication in top-tier journals may depend on different factors and collaboration patterns compared to the number of citations an article receives.
|
|
| 7. |
- McKelvey, Tomas, 1966, et al.
(författare)
-
The Influence of Collaboration on Firm Publications: Evidence from Pharmaceutical Cancer Research
- 2014
-
Ingår i: 15th International Conference of the International Joseph A. Schumpeter Society (ISS), hosted by the Friedrich Schiller University Jena, Germany, 27–30 July, 2014.. ; 2014:D10, s. 1-32
-
Konferensbidrag (refereegranskat)abstract
- Although bio-pharmaceutical companies engage intensely in collaboration as well as in scientific publications it is not well understood how and why the choice of distinct partner types affects the quality of companies’ scientific publications. We contribute to this gap in the existing literature by analyzing whether collaboration with particular types of partners and whether network embeddedness influences the quality of publications in cancer research, and specifically of the scientific publications of biotech and of pharmaceutical companies. Our empirical analysis employs two different measures for scientific quality, publication in top-tier journals and the number of forward citations. The results suggest that publication in top-tier journals may depend on different factors and collaboration patterns compared to the number of citations an article receives.
|
|
| 8. |
- Assmus, Anne, et al.
(författare)
-
How do personal networks affect successful drug development? An analysis of scientists networks in clinical trials
- 2016
-
Ingår i: 16th International Schumpeter Conference, Montreal, Canada, 5th-8th July 2016.
-
Konferensbidrag (refereegranskat)abstract
- The question of how to increase the efficiency and success of clinical research has gained considerable interest in recent years among researchers and managers of pharmaceutical companies, hospitals and healthcare organizations. This is part of a broader debate on the reorganization of the industry’s clinical research activities in order to decrease high attrition rates and foster clinical trial success, given the increasing costs associated with drug development (DiMasi et al., 2016; Munos, 2009; FDA, 2004). Principal investigators (PIs) - i.e., the lead scientists of clinical trials - are expected to have a major influence on key factors for successful clinical research. On the one hand, they bring in expertise in both basic and clinical research (Assmus and Haeussler, 2015); and on the other hand, they are embedded in social networks reflecting the collective nature of innovative and scientific activities (Oettl, 2012). Advocates of sparse network structures emphasize its opportunities for brokerage and for knowledge creation (McFadyen et al., 2009; Fleming et al., 2007; Burt, 2004); while a different stream of literature argues that network closure is more conducive to knowledge creation since it allows for the transfer of complex and sensitive knowledge (Reagans and McEvily, 2003). However, this debate has largely ignored the importance of the actors’ knowledge domains (Kilduff and Brass, 2010). We contribute to the literature by analyzing how the predominant knowledge domains of PIs affect the benefits obtained from by the network structure. More precisely, we analyze how the interplay between PIs’ scientific specialization into different knowledge domains in terms of publications in basic or clinical research journals and the structure of their networks in terms of brokerage and closure affect the outcome of clinical trials.
|
|
| 9. |
- Rake, Bastian, et al.
(författare)
-
How do networks affect knowledge generation for drug development? A study of investigator networks, knowledge domains and knowledge generation
- 2017
-
Ingår i: The 77th Annual Meeting of the Academy of Management, Atlanta, GA, USA, August 4-8, 2017. - : Academy of Management.
-
Konferensbidrag (refereegranskat)abstract
- This paper builds upon the intense and ongoing debate on whether and under which conditions network structures characterized by closure or structural holes support knowledge generation. In contrast to most of the existing literature we take the interplay between network structure and actor diversity in terms of actors’ knowledge domains into account. Our empirical analysis uses a unique dataset of investigator teams in clinical trials and their publication activities. Our preliminary results do not suggest a clear-cut association between bridging structural holes and trial related publication activities. While network closure within investigator teams may negatively affect publication outcomes, closure acts as an enabling factor for the interpretation and application of diverse knowledge within investigator teams which supports the emergence of trial related publications. These findings have important implications for managers in the biotechnology and pharmaceutical industry with respect to the composition of investigators teams as well as for the emerging concept of translation research intended to promote knowledge generation and innovative activities in these industries.
|
|
| 10. |
- Rake, Bastian, et al.
(författare)
-
Unlocking the importance of alliance partners for the quality and impact of company publications
- 2017
-
Ingår i: Presentation at conference "Knowledge and Universities: Impact on science, industry and policy", IIE, University of Gothenburg, Gothenburg, Sweden, 11-13 September 2017.
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- Recent research suggests that companies, particularly in science-based industries, publish scientific articles in order to achieve strategic goals. Since they often do so in collaboration with other organizations, this paper takes the next step by analyzing the influence of the number as well as the type of alliance partner on publication quality and impact. To make this argument, we analyze publications involving biotechnology or pharmaceutical companies and compare the results to publications that do not involve a company. The empirical analysis is based upon a unique dataset in pharmaceutical cancer research. The results indicate that companies need to carefully select their R&D alliance partners. More surprisingly, our results indicate that although the returns of additional partners may be diminishing, companies should focus on establishing R&D alliances with other companies to increase the probability of high-quality scientific publications.
|
|
